Pages

▼
Showing posts with label immunotherapy. Show all posts
Showing posts with label immunotherapy. Show all posts
January 10, 2014

Disfigurement, Discomfort, Death

›
+273% 1-year stock performance, January 7, 2013 to January 7, 2014, no insider sales +135% 1-month (roughly) performance, December 9,...
June 2, 2013

$PVCT's PV-10: A Targeted Therapy & An Immunotherapy

›
PV-10 works better, faster and longer. It appears there's a lot of excitement coming out of ASCO 2013 regarding immunotherapies, such ...
May 4, 2013

@PropThinker's Undervaluation of Vical’s Full Pipeline Allows A Cheap Bet on Cancer Trial (and $PVCT)

›
PropThink  provides actionable analysis of publicly-traded, emerging growth companies in the healthcare sector to retail and institutional i...
December 13, 2012

$PVCT: Blog Reader Question

›
I really appreciate your posts. Please keep them coming. One issue that I am having with the continued lack of any licensing agreement or i...
November 10, 2012

$PVCT.OB: When Does PV-10 Fail?

›
"Put enough water onto the fire, and it goes out." The compassionate use program, where doctors have significantly more flexibil...
November 4, 2012

$PVCT.OB Blog Reader Question

›
I read an old interview (2010) with Craig Dees where he explained the novelty of their approach in targeting the tumor as opposed to just u...
November 1, 2012

$PVCT.OB: Blog Reader Questions

›
Would a repeat of the study with HCC and melanoma cell lines  make sense using pancreatic and breast cancer cell lines? If so, would that b...
October 30, 2012

$PVCT.OB: The Orthogonality Paradigm

›
Yesterday's PR of Craig et al.'s poster at SITC highlighted additional data that demonstrated the use of PV-10 in combination with ...